Clinical study on Kanglaite Injection combined with icotinib in treatment of nonsmall cell lung cancer
Author(s): YANG Wei-jing, Department of Medicine, the Third Central Hospital of Baoding
Pages: 1984-1987
Year: 2016 Issue: 12
Journal: World Phytomedicines
Keyword: Kanglaite Injection; Icotinib Hydrochloride Tablets; non-small cell lung cancer; quality of life; immune function;
Abstract: Objective To evaluate the clinical effect of Kanglaite Injection combined with icotinib in treatment of non-small cell lung cancer. Methods Patients（86 cases） with non-small cell lung cancer in the Third Central Hospital of Baoding from April 2013 to August 2015 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were po administered with Icotinib Hydrochloride Tablets, 125 mg/time, three times daily. Patients in the treatment group were iv administered with Kanglaite Injection on the basis of the control group, 200 m L/time, once daily. Patients in two groups were treated for 3 courses, 1 course of 21 d, treatment interval of 3 — 5 d. After treatment, the clinical efficacies were evaluated, and quality of life and immune function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 34.88% and 60.47%, respectively, the clinical benefit rates in the control and treatment groups were 69.77% and 88.37%, respectively, and there was difference between two groups（P < 0.05）. After treatment, the improvement rates in the control and treatment groups were 34.88% and 58.14%, respectively, and there was difference between two groups（P < 0.05）. After treatment, CD3+, CD4+, CD4+/CD8+, and NK in the treatment group were higher than those before treatment, and the difference was statistically significant in the same group（P < 0.05）. And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups（P < 0.05）. Conclusion Kanglaite Injection combined with icotinib has clinical curative effect in treatment of non-small cell lung cancer, can improve quality of life, and increase immune function, which has a certain clinical application value.
Pages: 1984-1987
Year: 2016 Issue: 12
Journal: World Phytomedicines
Keyword: Kanglaite Injection; Icotinib Hydrochloride Tablets; non-small cell lung cancer; quality of life; immune function;
Abstract: Objective To evaluate the clinical effect of Kanglaite Injection combined with icotinib in treatment of non-small cell lung cancer. Methods Patients（86 cases） with non-small cell lung cancer in the Third Central Hospital of Baoding from April 2013 to August 2015 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were po administered with Icotinib Hydrochloride Tablets, 125 mg/time, three times daily. Patients in the treatment group were iv administered with Kanglaite Injection on the basis of the control group, 200 m L/time, once daily. Patients in two groups were treated for 3 courses, 1 course of 21 d, treatment interval of 3 — 5 d. After treatment, the clinical efficacies were evaluated, and quality of life and immune function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 34.88% and 60.47%, respectively, the clinical benefit rates in the control and treatment groups were 69.77% and 88.37%, respectively, and there was difference between two groups（P < 0.05）. After treatment, the improvement rates in the control and treatment groups were 34.88% and 58.14%, respectively, and there was difference between two groups（P < 0.05）. After treatment, CD3+, CD4+, CD4+/CD8+, and NK in the treatment group were higher than those before treatment, and the difference was statistically significant in the same group（P < 0.05）. And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups（P < 0.05）. Conclusion Kanglaite Injection combined with icotinib has clinical curative effect in treatment of non-small cell lung cancer, can improve quality of life, and increase immune function, which has a certain clinical application value.
Related Articles